Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06229678 · ClinicalTrials.gov registry record · Early Phase 1
Ketones, SGLT2, HFrEF
A Early Phase 1 study of Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT06229678: Recruiting Early Phase 1 study of Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction, sponsored by The University of Texas Health Science Center at San Antonio.
NCT06229678 is a Early Phase 1 study of Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 71 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06229678, a Early Phase 1 study of Type 2 Diabetes and Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great avidity by the myocardium, to measure change in Left Ventricle diastolic and systolic function
Primary Outcome
A measure of phosphocreatine change from baseline to study end
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin 25 MG Oral Tablet
- DRUG Acipimox 250 Mg Oral Capsule
Study Locations (1)
Texas
- Texas Diabetes Institute - University Health System - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2027-03-01 |
| Phase | Early Phase 1 |
What NCT06229678 shows while recruiting
NCT06229678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06229678 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06229678 about?
NCT06229678 is a clinical study titled "Ketones, SGLT2, HFrEF". The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great a...
What is the current status of trial NCT06229678?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 71 participants. The study started on 2024-01-25. Estimated completion is 2027-03-01.
What conditions does trial NCT06229678 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT06229678?
The interventions under investigation include: Placebo (DRUG), Empagliflozin 25 MG Oral Tablet (DRUG), Acipimox 250 Mg Oral Capsule (DRUG).
Who is sponsoring clinical trial NCT06229678?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06229678 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06229678's enrollment target sits among peer trials
71 183rd of 327 higher than 145 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
-
SGLT2i, Hepatic Glucose Production, and SNS
RECRUITING · Early Phase 1
-
Precision Dosing of Metformin in Youth With T2D
RECRUITING · Early Phase 1
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
RECRUITING · Early Phase 1
-
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
RECRUITING · Early Phase 1
-
Type 2 Diabetes and Blood Brain Barrier Improvement
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- NCT06782555 · 71 participants · Phase 1
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI